

REMARKS

In an Office Action dated August 5, 2002, the examiner asserted that restriction to one of the following inventions is required under 35 U.S.C. §121:

I. Claims 1 and 2, drawn to a method of screening agonists of GPR22 capable of being an appetite control agent;

II. Claims 1 and 2, drawn to a method of screening antagonists of GPR22 capable of being an appetite control agent;

III. Claims 3 and 5, drawn to a method of using an agonist of GPR22 as an appetite control agent;

IV. Claims 4 and 5, drawn to a method of using an antagonist of GPR22 as an appetite control agent;

V. Claim 6, drawn to an antisense oligonucleotide;

VI. Claims 7 and 9, drawn to a dominant negative mutant of GPR22;

VII. Claims 8 and 9, drawn to a dominant positive mutant of GPR22;

VIII. Claims 10 and 11, drawn to a transgenic non-human animal in GPR22 has been deleted;


IX. Claim 12, drawn to an antibody against GPR22.

Applicants hereby elect for initial prosecution on the merits the claims of Group II, i.e., claims 1 and 2, drawn to a method of screening antagonists of GPR22 capable of being an appetite control agent. Applicants specifically reserve the right to file one or more divisional applications directed to the subject matter of the non-elected claims.

The Office has noted that the present application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 because the sequences in Tables 1 and 2, pages 14-15, do not contain

proper references to SEQ ID Nos. In response to this objection and to the Notice to Comply with Sequence Requirements which accompanies the Office Action (response copy enclosed), Applicants have amended the specification to include proper reference to the SEQ ID Nos. already contained in the previously filed Sequence Listing.

The previously filed Sequence Listing was filed August 30, 2001 in response to a Notice to File Missing Parts mailed May 31, 2001, and included a computer readable form, paper copy and Statement under 37 C.F.R. §§ 1.821-1.825. This Sequence Listing lists all sequences disclosed in the specification, including the sequences in Tables 1 and 2. Applicants therefore submit that the present application now fully complies with the requirements under 37 C.F.R. §§ 1.821-1.825. Applicants request favorable consideration on the merits at this time.

<input checked="" type="checkbox"/>	Customer Number or Bar Code Label 6449				
Name	Martha Cassidy, Reg. No. 44,060				
Signature				Date	10/7/02
Address	Rothwell, Figg, Ernst & Manbeck Suite 800, 1425 K Street, N.W.				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

1991-196.AM1

Marked-Up Version of the Amended Specification

Pages 14-15, Table 1

Table 1

Human GPR22 cDNA sequence

Genbank accession number U66581

gttattttcttcaaaaggaaaacacaattttcttttatatcaaaacaatgcaaacttgatg
gttcttaattctacattttctattaatagtttacaaacttaaaaattaaactaagtacac
aattgaaagattttttttttcttacaagaacacggtatatacgtcatttaaattgccaaata
tcaaatagtttattctattttcactttctagggaaaaaaaccaactgctccaaaagaatgt
gtttttctcccattctggaaatcaacatgcagtcgaatctaacattacagtgcgagatg
acattgatgacatcaacaccaatatgtaccaaccactatcatatccgttaagctttcaag
tgtctctcaccggattttcttatgttagaaattgtgttgggacttggcagcaacctcactg
tattggtactttactgcatgaaatccaacttaatcaactctgtcagtaacattattacaa
tgaatcttcatgtacttgatgtaataatttgtgtgggatgtattcctctaactatagtta
tccttctgctttcactggagagtaacactgctctcatttgctgtttccatgaggcttggtg
tatcttttgcaagtgtctcaacagcaatcaacggtttttgctatcactttggacagatatg
acatctctgtaaaacctgcaaaccgaattctgacaatgggcagagctgtaatgttaatga
tatccatttggaattttttttttctctttcctgattcctttttattgaggtaaatTTTT
tcagtcttcaaagtggaaataacctgggaaaacaagacacttttatgtgtcagtacaaatg
aatactacactgaactgggaatgtattatcacctgttagtacagatcccaatattctttt
tcaactgttgtagtaattgttaatcacatacaccaaaataacttcaggctcttaatatcga
taggcacaagattttcaacagggcagaagaagaaagcaagaaagaaaaagacaattttctc
taaccacacaacatgaggctacagacatgtcacaaagcagtgggtgggagaaatgtagtct
ttgggtgaagaacttcagtttctgtaataattgccctccggcgagctgtgaaacgacacc
gtgaacgacgagaaagacaaaagagagtcttcaggatgtctttattgattattttctacat
ttcttctctgctggacaccaattttctgttttaataaccaccatttttatgtttaggcccaa
gtgaccttttagtaaaattaagattgtgttttttagtcatggcttatggaacaactatat
ttcaccctctattatatgcattcactagacaaaaatttcaaaaggcttggaaaagtaaaa
tgaaaaagcgagttgtttctatagtagaagctgatccctgcctaataatgctgtaatac
acaactcttggaatagatcccaaaagaaacaaaaaaattacctttgaagatagtgaataa
gagaaaaacgttttagtgcctcagggtgtcacagactagagaaaagtctcagtttcaccaa

atccacattcaaagaggttttaaatTTAAATTGTAAAACTGATATTACTGCCAAATATA
agaaaaatatTTTAAGTATTGGTTATGTTGTAAATTTTCAATGTGAAATGCTAATTAGAT
aggTCATATATATTCAATTTCTTCATTACTTAATGTATTTGTTGTCATGGCAGTTTGTTAA
agtactatcatgtgtatatTTTTGTCAATATTATGTCCAACAGAAAATATTcatgtaagtc
atTTTTTTTAAGGAATAAATACATAGCCTTAAACAGTGTATAACTTTAAATGTAAAA
aaaaaaaaaaaaaaaaaaaaaa (SEQ ID NO:1)

Page 15, Table 2

Table 2

Human GPR22 amino acid sequence
EMBL accession number Q99680

MCFSPILEINMQSESNITVRDDIDDINTNMYQPLSYPLSFQVSLTGFLMLEIVLGLGSNLTVL
VLYCMKSNLINSVSNIITMNLHVLVDVVICVGCIPLTIVILLLSLESNTALICCFHEACVSFAS
VSTAINVFAITLDRYDISVKPANRILTMGRAVMLMISIWIFSFFSFLIPFIEVNFFSLQSGNT
WENKTL LCVSTNEYYTELGMYHLLVQIPIFFFTVVVMLITYTKILQALNIRIGTRFSTGQKK
KARKKKTISLTTQHEATDMSQSSGGRNVVFGVRTSVSVIIALRRAVKRRHRERRERQKRVFRMS
LLIISTFLLCWTPISVLNTTILCLGPSDLLVKLRCLFLVMAYGTTIFHPLLYAFTRQKFQKVL
KSKMKKRVSIVEADPLPNNAVIHNSWIDPKRNKKITFEDSEIREKRLVPQVVTD
(SEQ ID NO:2)